
1. Lancet. 2021 Oct 30;398(10311):1566-1567. doi: 10.1016/S0140-6736(21)02228-5.
Epub 2021 Oct 28.

Unclear conclusions on SARS-CoV-2 elimination versus mitigation - Authors' reply.

Oliu-Barton M(1), Pradelski BSR(2), Aghion P(3), Artus P(4), Kickbusch I(5),
Lazarus JV(6), Vanderslott S(7).

Author information: 
(1)Université Paris Dauphine-PSL, Paris, France; Bruegel, Belgium; Esade Centre
for Economic Policy, Barcelona, Spain.
(2)French National Centre of Scientific Research (CNRS), 38058 Grenoble, France; 
Oxford-Man Institute of Quantitative Finance, University of Oxford, Oxford, UK.
Electronic address: bary.pradelski@cnrs.fr.
(3)Collège de France, Paris, France; London School of Economics and Political
Science, London, UK; INSEAD, Fontainebleau, France.
(4)Natixis, Paris, France; Paris School of Economics, Paris, France.
(5)Global Health Centre, Graduate Institute of International and Development
Studies, Geneva, Switzerland.
(6)Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University 
of Barcelona, Barcelona, Spain.
(7)Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine,
University of Oxford, Oxford, UK.

Comment on
    Lancet. 2021 Oct 30;398(10311):1566.

DOI: 10.1016/S0140-6736(21)02228-5 
PMCID: PMC8553273
PMID: 34755623  [Indexed for MEDLINE]

Conflict of interest statement: IK is a member of the Global Preparedness
Monitoring Board. JVL is a member of the Lancet COVID-19 Commission Public Health
Taskforce. SV is a member of Team Halo (London School of Hygiene & Tropical
Medicine, the UN, and Gavi, the Vaccine Alliance). All other authors declare no
competing interests.

